You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameResveratrol
Accession NumberDB02709  (EXPT02968)
TypeSmall Molecule
GroupsExperimental, Investigational
DescriptionResveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as two structural isomers: cis-(Z) and trans-(E), with the trans-isomer shown in the top image. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature. [Wikipedia]
Structure
Thumb
Synonyms
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(E)-resveratrol
3,4',5-Stilbenetriol
3,4',5-trihydroxy-stilbene
3,4',5-Trihydroxystilbene
trans-3,4',5-trihydroxystilbene
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Co-veratrolHome Aide Diagnostics, Inc.
SaltsNot Available
Categories
UNIIQ369O8926L
CAS number501-36-0
WeightAverage: 228.2433
Monoisotopic: 228.07864425
Chemical FormulaC14H12O3
InChI KeyInChIKey=LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
IUPAC Name
5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
SMILES
OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassStilbenes
Sub ClassNot Available
Direct ParentStilbenes
Alternative Parents
Substituents
  • Stilbene
  • Styrene
  • Resorcinol
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationBeing investigated for the treatment of Herpes labialis infections (cold sores).
PharmacodynamicsResveratrol, a phytoalexin, has been found to inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a dose-dependent, reversible manner, although this is only one of its many pharmaceutical properties. In some countries where there is higher consumption of red wine, there appears to be a lower incidence of heart disease. Other benefits of resveratrol include its anti-inflammatory and antioxidant effects. In preclinical studies, Resveratrol has been found to have potential anticancer properties.
Mechanism of actionResveratrol suppresses NF-kappaB (NF-kappaB) activation in HSV infected cells. Reports have indicated that HSV activates NF-kappaB during productive infection and this may be an essential aspect of its replication scheme [PMID: 9705914].
Related Articles
AbsorptionHigh absorption but very low bioavailability.
Volume of distributionNot Available
Protein bindingStrong affinity towards protein binding.
Metabolism

Hepatic. Rapidly metabolized and excreted.

SubstrateEnzymesProduct
Resveratrol
piceatannol (3,5,3',4'-tetrahydroxystilbene)Details
Resveratrol
tetrahydroxystilbene M1Details
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.59
Caco-2 permeable+0.8915
P-glycoprotein substrateNon-substrate0.6501
P-glycoprotein inhibitor INon-inhibitor0.9266
P-glycoprotein inhibitor IINon-inhibitor0.9612
Renal organic cation transporterNon-inhibitor0.8634
CYP450 2C9 substrateNon-substrate0.7519
CYP450 2D6 substrateNon-substrate0.9288
CYP450 3A4 substrateNon-substrate0.7143
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.7068
CYP450 2D6 inhibitorNon-inhibitor0.9226
CYP450 2C19 inhibitorInhibitor0.8052
CYP450 3A4 inhibitorInhibitor0.7539
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8559
Ames testNon AMES toxic0.8407
CarcinogenicityNon-carcinogens0.7825
BiodegradationNot ready biodegradable0.8499
Rat acute toxicity1.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8933
hERG inhibition (predictor II)Non-inhibitor0.9462
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point254 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0688 mg/mLALOGPS
logP2.57ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.49ChemAxon
pKa (Strongest Basic)-6.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area60.69 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.46 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (3 TMS)splash10-0006-1853900000-4919511a11ec24935434View in MoNA
GC-MSGC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Philippe Jeandet, Roger Bessis, Marielle Adrian, Jean-Claude Yvin, Jean-Marie Joubert, “Use of aluminium chloride as a resveratrol synthesis elicitor.” U.S. Patent US6080701, issued August, 1991.

US6080701
General References
  1. Farina A, Ferranti C, Marra C: An improved synthesis of resveratrol. Nat Prod Res. 2006 Mar;20(3):247-52. [PubMed:16401555 ]
  2. Renaud S, Ruf JC: The French paradox: vegetables or wine. Circulation. 1994 Dec;90(6):3118-9. [PubMed:7994864 ]
  3. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB: An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002 Jan 30;50(3):431-5. [PubMed:11804508 ]
  4. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J, van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003 Sep 24;51(20):5867-70. [PubMed:13129286 ]
  5. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 Dec;32(12):1377-82. Epub 2004 Aug 27. [PubMed:15333514 ]
  6. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M: Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol. 2008 Feb 1;75(3):677-87. Epub 2007 Sep 18. [PubMed:17959154 ]
  7. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999 Oct;43(3):145-55. [PubMed:10551373 ]
  8. N' soukpoe-Kossi CN, St-Louis C, Beauregard M, Subirade M, Carpentier R, Hotchandani S, Tajmir-Riahi HA: Resveratrol binding to human serum albumin. J Biomol Struct Dyn. 2006 Dec;24(3):277-83. [PubMed:17054386 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (16.6 KB)
Interactions
Drug Interactions
Drug
AbciximabResveratrol may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Resveratrol.
AbirateroneThe serum concentration of Resveratrol can be increased when it is combined with Abiraterone.
AcebutololResveratrol may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aceclofenac.
AcenocoumarolResveratrol may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Resveratrol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Resveratrol.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Resveratrol.
Alendronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Alendronic acid.
AliskirenResveratrol may decrease the antihypertensive activities of Aliskiren.
AlprenololResveratrol may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Resveratrol.
AlprostadilAlprostadil may increase the antiplatelet activities of Resveratrol.
AlteplaseResveratrol may increase the anticoagulant activities of Alteplase.
ALX-0081Resveratrol may increase the anticoagulant activities of ALX-0081.
AmikacinResveratrol may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideResveratrol may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.
AnagrelideResveratrol may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Resveratrol.
AncrodResveratrol may increase the anticoagulant activities of Ancrod.
AnistreplaseResveratrol may increase the anticoagulant activities of Anistreplase.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Resveratrol.
Antithrombin III humanResveratrol may increase the anticoagulant activities of Antithrombin III human.
ApixabanResveratrol may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Apremilast.
ArdeparinResveratrol may increase the anticoagulant activities of Ardeparin.
ArgatrobanResveratrol may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Resveratrol.
ArotinololResveratrol may decrease the antihypertensive activities of Arotinolol.
AstaxanthinResveratrol may increase the anticoagulant activities of Astaxanthin.
AtenololResveratrol may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Resveratrol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.
AzithromycinThe metabolism of Resveratrol can be decreased when combined with Azithromycin.
BalsalazideResveratrol may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Resveratrol.
BatroxobinResveratrol may increase the anticoagulant activities of Batroxobin.
BecaplerminResveratrol may increase the anticoagulant activities of Becaplermin.
BefunololResveratrol may decrease the antihypertensive activities of Befunolol.
BemiparinResveratrol may increase the anticoagulant activities of Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Resveratrol.
BenoxaprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Benoxaprofen.
BeraprostResveratrol may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Resveratrol.
BetaxololResveratrol may decrease the antihypertensive activities of Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Resveratrol.
BevantololResveratrol may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Resveratrol.
BisoprololResveratrol may decrease the antihypertensive activities of Bisoprolol.
BivalirudinResveratrol may increase the anticoagulant activities of Bivalirudin.
BopindololResveratrol may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Resveratrol can be decreased when combined with Bortezomib.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.
BufuralolResveratrol may decrease the antihypertensive activities of Bufuralol.
BumetanideResveratrol may decrease the diuretic activities of Bumetanide.
BupranololResveratrol may decrease the antihypertensive activities of Bupranolol.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.
CaffeineThe metabolism of Resveratrol can be decreased when combined with Caffeine.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Resveratrol.
CangrelorResveratrol may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Resveratrol.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.
CarbamazepineThe metabolism of Resveratrol can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Resveratrol.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Resveratrol.
CarteololResveratrol may decrease the antihypertensive activities of Carteolol.
CarvedilolResveratrol may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Resveratrol.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Resveratrol.
CeliprololResveratrol may decrease the antihypertensive activities of Celiprolol.
CertoparinResveratrol may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Resveratrol.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Resveratrol.
CholestyramineCholestyramine can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.
CilostazolResveratrol may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Resveratrol.
CitalopramThe metabolism of Resveratrol can be decreased when combined with Citalopram.
Citric AcidResveratrol may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clonixin.
ClopidogrelResveratrol may increase the anticoagulant activities of Clopidogrel.
ClopidogrelClopidogrel may increase the antiplatelet activities of Resveratrol.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Resveratrol.
ClotrimazoleThe metabolism of Resveratrol can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Resveratrol resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Resveratrol.
CyclosporineResveratrol may increase the nephrotoxic activities of Cyclosporine.
Cyproterone acetateThe serum concentration of Resveratrol can be decreased when it is combined with Cyproterone acetate.
D-LimoneneThe risk or severity of adverse effects can be increased when Resveratrol is combined with D-Limonene.
Dabigatran etexilateResveratrol may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinResveratrol may increase the anticoagulant activities of Dalteparin.
DanaparoidResveratrol may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Resveratrol.
DaunorubicinResveratrol may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Resveratrol can be increased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.
DefibrotideResveratrol may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Resveratrol.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic Acid.
DesirudinResveratrol may increase the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Resveratrol.
DesmopressinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.
DesmoteplaseResveratrol may increase the anticoagulant activities of Desmoteplase.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Resveratrol.
DextranResveratrol may increase the anticoagulant activities of Dextran.
Dextran 40Resveratrol may increase the anticoagulant activities of Dextran 40.
Dextran 70Resveratrol may increase the anticoagulant activities of Dextran 70.
Dextran 75Resveratrol may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Resveratrol.
DicoumarolResveratrol may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Resveratrol.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Resveratrol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.
DigoxinDigoxin may decrease the cardiotoxic activities of Resveratrol.
DihydrostreptomycinResveratrol may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Resveratrol.
DipyridamoleResveratrol may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Resveratrol.
DitazoleResveratrol may increase the anticoagulant activities of Ditazole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.
DoxorubicinResveratrol may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneResveratrol may increase the hyperkalemic activities of Drospirenone.
Drotrecogin alfaResveratrol may increase the anticoagulant activities of Drotrecogin alfa.
DroxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Droxicam.
Edetic AcidResveratrol may increase the anticoagulant activities of Edetic Acid.
EdoxabanResveratrol may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Resveratrol.
EnoxaparinResveratrol may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the antiplatelet activities of Resveratrol.
EpirizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Epirizole.
EpirubicinResveratrol may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneResveratrol may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Resveratrol.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Resveratrol.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Resveratrol.
EptifibatideResveratrol may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Resveratrol.
EsmololResveratrol may decrease the antihypertensive activities of Esmolol.
Etacrynic acidResveratrol may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.
Ethyl biscoumacetateResveratrol may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Resveratrol.
EtofenamateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Resveratrol.
Evening primrose oilThe risk or severity of adverse effects can be increased when Resveratrol is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Resveratrol is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Resveratrol.
FibrinolysinResveratrol may increase the anticoagulant activities of Fibrinolysin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Resveratrol.
FlunixinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Resveratrol.
FluvoxamineThe metabolism of Resveratrol can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Resveratrol.
Fondaparinux sodiumResveratrol may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Resveratrol.
FramycetinResveratrol may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideResveratrol may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Resveratrol.
GentamicinResveratrol may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Resveratrol.
HaloperidolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.
HeparinResveratrol may increase the anticoagulant activities of Heparin.
HirulogResveratrol may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Resveratrol is combined with HMPL-004.
HydralazineResveratrol may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Resveratrol.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.
Hygromycin BResveratrol may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol.
IbudilastResveratrol may increase the antiplatelet activities of Ibudilast.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Resveratrol.
IbuproxamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Resveratrol is combined with Icatibant.
Icosapent ethylResveratrol may increase the antiplatelet activities of Icosapent ethyl.
IdarubicinResveratrol may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IfenprodilResveratrol may increase the antiplatelet activities of Ifenprodil.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Resveratrol.
IloprostIloprost may increase the antiplatelet activities of Resveratrol.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.
IndenololResveratrol may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Resveratrol.
IndoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.
IsoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Isoxicam.
KanamycinResveratrol may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Resveratrol.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.
LabetalolResveratrol may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Resveratrol.
LepirudinResveratrol may increase the anticoagulant activities of Lepirudin.
LevobunololResveratrol may decrease the antihypertensive activities of Levobunolol.
LidocaineThe metabolism of Resveratrol can be decreased when combined with Lidocaine.
LimaprostLimaprost may increase the antiplatelet activities of Resveratrol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Resveratrol.
LithiumThe serum concentration of Lithium can be increased when it is combined with Resveratrol.
LornoxicamThe risk or severity of adverse effects can be increased when Resveratrol is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.
LoxoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Resveratrol.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Resveratrol.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Resveratrol.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Resveratrol.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Resveratrol.
MesalazineResveratrol may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Resveratrol.
MetamizoleThe risk or severity of adverse effects can be increased when Resveratrol is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Resveratrol.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Resveratrol.
MetipranololResveratrol may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.
MetoprololResveratrol may decrease the antihypertensive activities of Metoprolol.
MetrizamideResveratrol may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe metabolism of Resveratrol can be decreased when combined with Mexiletine.
MilrinoneMilrinone may increase the antiplatelet activities of Resveratrol.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Resveratrol.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Resveratrol.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Resveratrol.
NadololResveratrol may decrease the antihypertensive activities of Nadolol.
NadroparinResveratrol may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Resveratrol.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Resveratrol.
NCX 4016The risk or severity of adverse effects can be increased when Resveratrol is combined with NCX 4016.
NeomycinResveratrol may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nepafenac.
NetilmicinResveratrol may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NevirapineThe metabolism of Resveratrol can be decreased when combined with Nevirapine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Resveratrol.
ObinutuzumabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Resveratrol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.
OlsalazineResveratrol may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Resveratrol.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Resveratrol.
OrgoteinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Orgotein.
OsimertinibThe serum concentration of Resveratrol can be decreased when it is combined with Osimertinib.
OtamixabanResveratrol may increase the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Resveratrol.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.
OxprenololResveratrol may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Oxyphenbutazone.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Resveratrol.
PamidronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Resveratrol is combined with Parecoxib.
ParnaparinResveratrol may increase the anticoagulant activities of Parnaparin.
ParomomycinResveratrol may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Peginterferon alfa-2bThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.
PenbutololResveratrol may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.
Pentosan PolysulfateResveratrol may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Resveratrol.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.
PhenindioneResveratrol may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Resveratrol can be increased when combined with Phenobarbital.
PhenprocoumonResveratrol may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Resveratrol.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Resveratrol.
PindololResveratrol may decrease the antihypertensive activities of Pindolol.
PiretanideResveratrol may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.
PlasminResveratrol may increase the anticoagulant activities of Plasmin.
PlicamycinResveratrol may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Resveratrol.
PractololResveratrol may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Resveratrol.
PrasugrelResveratrol may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Resveratrol.
PrimidoneThe metabolism of Resveratrol can be increased when combined with Primidone.
ProbenecidThe serum concentration of Resveratrol can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Propacetamol.
PropranololResveratrol may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Resveratrol.
Protein CResveratrol may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeResveratrol may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Resveratrol is combined with PTC299.
PuromycinResveratrol may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Resveratrol.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Resveratrol.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Resveratrol.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Resveratrol.
ReteplaseResveratrol may increase the anticoagulant activities of Reteplase.
ReviparinResveratrol may increase the anticoagulant activities of Reviparin.
RibostamycinResveratrol may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelRidogrel may increase the antiplatelet activities of Resveratrol.
RifampicinThe metabolism of Resveratrol can be increased when combined with Rifampicin.
RisedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.
RivaroxabanResveratrol may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Resveratrol.
RopiniroleThe metabolism of Resveratrol can be decreased when combined with Ropinirole.
RosiglitazoneResveratrol may increase the anticoagulant activities of Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Resveratrol.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Resveratrol.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Resveratrol.
SCH-530348Resveratrol may increase the antiplatelet activities of SCH-530348.
SelexipagResveratrol may increase the anticoagulant activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Seratrodast.
SevofluraneSevoflurane may increase the antiplatelet activities of Resveratrol.
SimeprevirThe metabolism of Resveratrol can be decreased when combined with Simeprevir.
SotalolResveratrol may decrease the antihypertensive activities of Sotalol.
SpectinomycinResveratrol may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Resveratrol.
SpironolactoneResveratrol may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Resveratrol is combined with SRT501.
StreptokinaseResveratrol may increase the anticoagulant activities of Streptokinase.
StreptomycinResveratrol may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinResveratrol may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineResveratrol may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Resveratrol.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Resveratrol.
SulodexideResveratrol may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.
TacrolimusResveratrol may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Resveratrol.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Resveratrol.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Resveratrol.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Resveratrol.
TenecteplaseResveratrol may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tenofovir.
TenofovirThe metabolism of Resveratrol can be decreased when combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Resveratrol.
TepoxalinThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tepoxalin.
TeriflunomideThe serum concentration of Resveratrol can be decreased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Resveratrol is combined with Teriflunomide.
TesmilifeneResveratrol may increase the antiplatelet activities of Tesmilifene.
TheophyllineThe metabolism of Resveratrol can be decreased when combined with Theophylline.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Resveratrol.
TicagrelorResveratrol may increase the anticoagulant activities of Ticagrelor.
TiclopidineResveratrol may increase the anticoagulant activities of Ticlopidine.
TiclopidineThe metabolism of Resveratrol can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tiludronate.
TimololResveratrol may decrease the antihypertensive activities of Timolol.
TinzaparinResveratrol may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Resveratrol.
TirofibanResveratrol may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Resveratrol.
TobramycinResveratrol may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Resveratrol.
TorasemideResveratrol may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Resveratrol.
TranilastThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.
TrapidilResveratrol may increase the antiplatelet activities of Trapidil.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Resveratrol.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Resveratrol.
TreprostinilResveratrol may increase the anticoagulant activities of Treprostinil.
TriamtereneResveratrol may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Resveratrol.
TriflusalResveratrol may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Resveratrol.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Resveratrol.
UrokinaseResveratrol may increase the anticoagulant activities of Urokinase.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Resveratrol.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Resveratrol.
VemurafenibThe serum concentration of Resveratrol can be increased when it is combined with Vemurafenib.
Vitamin EVitamin E may increase the antiplatelet activities of Resveratrol.
VorapaxarResveratrol may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Resveratrol.
WarfarinResveratrol may increase the anticoagulant activities of Warfarin.
XimelagatranResveratrol may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Resveratrol.
Zoledronic acidThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph dehydrogenase (quinone) activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO2
Uniprot ID:
P16083
Molecular Weight:
25918.4 Da
References
  1. Buryanovskyy L, Fu Y, Boyd M, Ma Y, Hsieh TC, Wu JM, Zhang Z: Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry. 2004 Sep 14;43(36):11417-26. [PubMed:15350128 ]
  2. Wang Z, Hsieh TC, Zhang Z, Ma Y, Wu JM: Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9. [PubMed:15381063 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein serine/threonine kinase activity
Specific Function:
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coor...
Gene Name:
CSNK2A1
Uniprot ID:
P68400
Molecular Weight:
45143.25 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085 ]
  2. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
  2. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F, Lucas D: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol. 2004 Aug 15;68(4):773-82. [PubMed:15276085 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Chang TK, Chen J, Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther. 2001 Dec;299(3):874-82. [PubMed:11714871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS: Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010 Sep;3(9):1168-75. doi: 10.1158/1940-6207.CAPR-09-0155. Epub 2010 Aug 17. [PubMed:20716633 ]
  2. Piver B, Berthou F, Dreano Y, Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 2001 Dec 15;125(1-3):83-91. [PubMed:11701226 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da
References
  1. Commodari F, Khiat A, Ibrahimi S, Brizius AR, Kalkstein N: Comparison of the phytoestrogen trans-resveratrol (3,4',5-trihydroxystilbene) structures from x-ray diffraction and solution NMR. Magn Reson Chem. 2005 Jul;43(7):567-72. [PubMed:15809979 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23